4//SEC Filing
Anacor Pharmaceuticals, Inc. 4
Accession 0000950103-16-014335
CIK 0001411158operating
Filed
Jun 23, 8:00 PM ET
Accepted
Jun 24, 2:49 PM ET
Size
29.2 KB
Accession
0000950103-16-014335
Insider Transaction Report
Form 4
Zane Lee
VP, Clinical Dev & Interim CMO
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2016-06-24−33,239→ 0 totalExercise: $6.92→ Common Stock (33,239 underlying) - Disposition to Issuer
Stock Option (right to buy)
2016-06-24−80,000→ 0 totalExercise: $6.96→ Common Stock (80,000 underlying) - Disposition to Issuer
Common Stock
2016-06-24$99.25/sh−44,194$4,386,255→ 0 total - Disposition to Issuer
Stock Option (right to buy)
2016-06-24−3,849→ 0 totalExercise: $5.00→ Common Stock (3,849 underlying) - Disposition to Issuer
Stock Option (right to buy)
2016-06-24−12,957→ 0 totalExercise: $7.25→ Common Stock (12,957 underlying) - Disposition to Issuer
Stock Option (right to buy)
2016-06-24−24,360→ 0 totalExercise: $37.81→ Common Stock (24,360 underlying) - Disposition to Issuer
Performance Restricted Stock Units
2016-06-24−6,350→ 0 total→ Common Stock (6,350 underlying) - Disposition to Issuer
Stock Option (right to buy)
2016-06-24−27,661→ 0 totalExercise: $5.59→ Common Stock (27,661 underlying) - Disposition to Issuer
Stock Option (right to buy)
2016-06-24−22,136→ 0 totalExercise: $78.91→ Common Stock (22,136 underlying) - Disposition to Issuer
Performance Restricted Stock Units
2016-06-24−4,375→ 0 total→ Common Stock (4,375 underlying) - Disposition to Issuer
Stock Option (right to buy)
2016-06-24−47,000→ 0 totalExercise: $17.14→ Common Stock (47,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2016-06-24−30,000→ 0 totalExercise: $12.49→ Common Stock (30,000 underlying)
Footnotes (2)
- [F1]As of the effective time of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 14, 2016 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Quattro Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent, pursuant to the terms of the Merger Agreement, (i) each share of the Issuer's Common Stock held by the reporting person was disposed of in exchange for the merger consideration of $99.25 per share, (ii) each award of restricted stock units (including performance restricted stock units) and stock options became fully vested and (iii) each award of restricted stock units (including performance restricted stock units) and stock options was cancelled in exchange for the right to receive a cash payment per share in an amount equal to $99.25 less, in the case of stock options, the applicable exercise price.
- [F2]Includes shares acquired pursuant to the Issuer's ESPP since the reporting person's last Form 4.
Documents
Issuer
Anacor Pharmaceuticals, Inc.
CIK 0001411158
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001411158
Filing Metadata
- Form type
- 4
- Filed
- Jun 23, 8:00 PM ET
- Accepted
- Jun 24, 2:49 PM ET
- Size
- 29.2 KB